Literature DB >> 23324976

Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

Louise Baandrup1, Maria Blomberg, Christian Dehlendorff, Carsten Sand, Klaus K Andersen, Susanne K Kjaer.   

Abstract

BACKGROUND: Approximately 90% of genital warts (GWs) are caused by human papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine to all 12-year-old girls since 2009 and catch-up vaccination to girls up to 15 years since 2008, with up to 80% to 85% vaccine coverage. We determined the incidence of GWs in Denmark since 1996, focusing on the period after licensing of HPV vaccination (October 2006).
METHODS: From the Danish National Patient Register, we identified all hospitalizations and outpatient consultations for GWs between January 1995 and July 2011. Poisson regression was used to estimate average annual percentage changes.
RESULTS: The overall incidence of GWs in women increased significantly until 2007, followed by an average yearly decline of 3.1% (95% confidence interval [CI], -5.5 to -0.7). In men, the incidence increased by 6.2% per year from 2004 (95% CI, 4.6-7.8). Stratifying on age, a significant decline was seen only for young women, particularly those aged 16 to 17 years, in whom GWs were virtually eliminated (average annual percentage change, -45.3%; 95% CI, -55.8 to -33.3). The incidences of genital Chlamydia, syphilis, and gonorrhea were stable or increased during the study period.
CONCLUSIONS: The incidence of GWs decreased substantially among women with high HPV vaccine coverage, pointing to the effect of the national HPV vaccination program.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324976     DOI: 10.1097/OLQ.0b013e31827bd66b

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  49 in total

1.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

2.  Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.

Authors:  Anthony E Yakely; Lital Avni-Singer; Carlos R Oliveira; Linda M Niccolai
Journal:  Sex Transm Dis       Date:  2019-04       Impact factor: 2.830

3.  Diverse Families' Experiences with HPV Vaccine Information Sources: A Community-Based Participatory Approach.

Authors:  Djin Lai; Julia Bodson; France A Davis; Doriena Lee; Fahina Tavake-Pasi; Edwin Napia; Jeannette Villalta; Valentine Mukundente; Ryan Mooney; Heather Coulter; Louisa A Stark; Ana C Sanchez-Birkhead; Deanna Kepka
Journal:  J Community Health       Date:  2017-04

4.  The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.

Authors:  Mélanie Drolet; Jean-François Laprise; Julia M L Brotherton; Basil Donovan; Christopher K Fairley; Hammad Ali; Élodie Bénard; Dave Martin; Marc Brisson
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226

5.  Overcoming barriers in HPV vaccination and screening programs.

Authors:  Alex Vorsters; Marc Arbyn; Marc Baay; Xavier Bosch; Silvia de Sanjosé; Sharon Hanley; Emilie Karafillakis; Pier Luigi Lopalco; Kevin G Pollock; Joanne Yarwood; Pierre Van Damme
Journal:  Papillomavirus Res       Date:  2017-07-20

6.  Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.

Authors:  J Obel; J McKenzie; L E Buenconsejo-Lum; A M Durand; A Ekeroma; Y Souares; D Hoy; W Baravilala; S M Garland; S K Kjaer; A Roth
Journal:  Asian Pac J Cancer Prev       Date:  2015

7.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Parents' views on human papillomavirus vaccination for sexually transmissible infection prevention: a qualitative study.

Authors:  Linda M Niccolai; Caitlin E Hansen; Marisol Credle; Sheryl A Ryan; Eugene D Shapiro
Journal:  Sex Health       Date:  2014-07       Impact factor: 2.706

9.  Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.

Authors:  Mauricio Hernández-Ávila; Leticia Torres-Ibarra; Margaret Stanley; Jorge Salmerón; Aurelio Cruz-Valdez; Nubia Muñoz; Rolando Herrero; Ignacio F Villaseñor-Ruíz; Eduardo Lazcano-Ponce
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

10.  Development and initial feedback about a human papillomavirus (HPV) vaccine comic book for adolescents.

Authors:  Mira L Katz; Benjamin R Oldach; Jennifer Goodwin; Paul L Reiter; Mack T Ruffin; Electra D Paskett
Journal:  J Cancer Educ       Date:  2014-06       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.